Xolair subcutaneous injection 150mg pen

Xolair subcutaneous injection 150mg pen (YJ code: 2290400G4020, standard: 150mg 1mL 1 kit) is a Novartis Pharma product containing Omalizumab (genetical recombination). It is used for moderate to severe persistent asthma in patients aged 6 years and older, chronic spontaneous urticaria in those 12 years and older, and chronic rhinosinusitis with nasal polyps in adults.